Elevation of fatty acid desaturase 2 in esophageal adenocarcinoma increases polyunsaturated lipids and may exacerbate bile acid-induced DNA damage.
Barrett's esophagus
FADS2
esophageal adenocarcinoma
lipid desaturation
lipid metabolism
Journal
Clinical and translational medicine
ISSN: 2001-1326
Titre abrégé: Clin Transl Med
Pays: United States
ID NLM: 101597971
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
revised:
22
03
2022
received:
24
11
2021
accepted:
27
03
2022
entrez:
13
5
2022
pubmed:
14
5
2022
medline:
18
5
2022
Statut:
ppublish
Résumé
The risk of esophageal adenocarcinoma (EAC) is associated with gastro-esophageal reflux disease (GERD) and obesity. Lipid metabolism-targeted therapies decrease the risk of progressing from Barrett's esophagus (BE) to EAC, but the precise lipid metabolic changes and their roles in genotoxicity during EAC development are yet to be established. Esophageal biopsies from the normal epithelium (NE), BE, and EAC, were analyzed using concurrent lipidomics and proteomics (n = 30) followed by orthogonal validation on independent samples using RNAseq transcriptomics (n = 22) and immunohistochemistry (IHC, n = 80). The EAC cell line FLO-1 was treated with FADS2 selective inhibitor SC26196, and/or bile acid cocktail, followed by immunofluorescence staining for γH2AX. Metabolism-focused Reactome analysis of the proteomics data revealed enrichment of fatty acid metabolism, ketone body metabolism, and biosynthesis of specialized pro-resolving mediators in EAC pathogenesis. Lipidomics revealed progressive alterations (NE-BE-EAC) in glycerophospholipid synthesis with decreasing triglycerides and increasing phosphatidylcholine and phosphatidylethanolamine, and sphingolipid synthesis with decreasing dihydroceramide and increasing ceramides. Furthermore, a progressive increase in lipids with C20 fatty acids and polyunsaturated lipids with ≥4 double bonds were also observed. Integration with transcriptome data identified candidate enzymes for IHC validation: Δ4-Desaturase, Sphingolipid 1 (DEGS1) which desaturates dihydroceramide to ceramide, and Δ5 and Δ6-Desaturases (fatty acid desaturases, FADS1 and FADS2), responsible for polyunsaturation. All three enzymes showed significant increases from BE through dysplasia to EAC, but transcript levels of DEGS1 were decreased suggesting post-translational regulation. Finally, the FADS2 selective inhibitor SC26196 significantly reduced polyunsaturated lipids with three and four double bonds and reduced bile acid-induced DNA double-strand breaks in FLO-1 cells in vitro. Integrated multiomics revealed sphingolipid and phospholipid metabolism rewiring during EAC development. FADS2 inhibition and reduction of the high polyunsaturated lipids effectively protected EAC cells from bile acid-induced DNA damage in vitro, potentially through reduced lipid peroxidation.
Sections du résumé
BACKGROUND
The risk of esophageal adenocarcinoma (EAC) is associated with gastro-esophageal reflux disease (GERD) and obesity. Lipid metabolism-targeted therapies decrease the risk of progressing from Barrett's esophagus (BE) to EAC, but the precise lipid metabolic changes and their roles in genotoxicity during EAC development are yet to be established.
METHODS
Esophageal biopsies from the normal epithelium (NE), BE, and EAC, were analyzed using concurrent lipidomics and proteomics (n = 30) followed by orthogonal validation on independent samples using RNAseq transcriptomics (n = 22) and immunohistochemistry (IHC, n = 80). The EAC cell line FLO-1 was treated with FADS2 selective inhibitor SC26196, and/or bile acid cocktail, followed by immunofluorescence staining for γH2AX.
RESULTS
Metabolism-focused Reactome analysis of the proteomics data revealed enrichment of fatty acid metabolism, ketone body metabolism, and biosynthesis of specialized pro-resolving mediators in EAC pathogenesis. Lipidomics revealed progressive alterations (NE-BE-EAC) in glycerophospholipid synthesis with decreasing triglycerides and increasing phosphatidylcholine and phosphatidylethanolamine, and sphingolipid synthesis with decreasing dihydroceramide and increasing ceramides. Furthermore, a progressive increase in lipids with C20 fatty acids and polyunsaturated lipids with ≥4 double bonds were also observed. Integration with transcriptome data identified candidate enzymes for IHC validation: Δ4-Desaturase, Sphingolipid 1 (DEGS1) which desaturates dihydroceramide to ceramide, and Δ5 and Δ6-Desaturases (fatty acid desaturases, FADS1 and FADS2), responsible for polyunsaturation. All three enzymes showed significant increases from BE through dysplasia to EAC, but transcript levels of DEGS1 were decreased suggesting post-translational regulation. Finally, the FADS2 selective inhibitor SC26196 significantly reduced polyunsaturated lipids with three and four double bonds and reduced bile acid-induced DNA double-strand breaks in FLO-1 cells in vitro.
CONCLUSIONS
Integrated multiomics revealed sphingolipid and phospholipid metabolism rewiring during EAC development. FADS2 inhibition and reduction of the high polyunsaturated lipids effectively protected EAC cells from bile acid-induced DNA damage in vitro, potentially through reduced lipid peroxidation.
Identifiants
pubmed: 35560527
doi: 10.1002/ctm2.810
pmc: PMC9099135
doi:
Substances chimiques
Bile Acids and Salts
0
Fatty Acids
0
Sphingolipids
0
Fatty Acid Desaturases
EC 1.14.19.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e810Informations de copyright
© 2022 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.
Références
Cancers (Basel). 2021 May 19;13(10):
pubmed: 34069611
J Enzyme Inhib Med Chem. 2018 Dec;33(1):1024-1033
pubmed: 29865880
Blood. 2020 Sep 10;136(11):1303-1316
pubmed: 32458004
Nat Rev Cancer. 2016 Nov;16(11):708-717
pubmed: 27562461
J Thorac Cardiovasc Surg. 2011 Feb;141(2):469-75, 475.e1-4
pubmed: 20880550
Science. 1956 Aug 10;124(3215):269-70
pubmed: 13351639
Cell Chem Biol. 2019 Jan 17;26(1):71-84.e4
pubmed: 30415965
Gut. 2007 Jun;56(6):763-71
pubmed: 17145738
Anal Chem. 2006 Jul 1;78(13):4281-90
pubmed: 16808434
Mol Clin Oncol. 2017 Feb;6(2):139-153
pubmed: 28357082
Aliment Pharmacol Ther. 2010 Feb 1;31(3):440-51
pubmed: 19843025
J Clin Pathol. 2005 Apr;58(4):343-51
pubmed: 15790695
Future Med Chem. 2016 Dec;8(18):2169-2171
pubmed: 27845593
J Exp Clin Cancer Res. 2019 Jan 9;38(1):13
pubmed: 30626422
Biomolecules. 2020 May 16;10(5):
pubmed: 32429496
Sci Rep. 2019 Nov 8;9(1):16313
pubmed: 31705020
Redox Biol. 2021 May;41:101894
pubmed: 33621787
Nature. 2019 Feb;566(7744):403-406
pubmed: 30728499
BMC Bioinformatics. 2008 Nov 28;9:504
pubmed: 19040729
Biophys J. 2016 Apr 26;110(8):1800-1810
pubmed: 27119640
Oncotarget. 2017 Apr 11;8(15):25080-25096
pubmed: 28212575
Front Immunol. 2021 Jun 30;12:702785
pubmed: 34276698
Exp Mol Med. 2016 Nov 25;48(11):e272
pubmed: 27885254
Nat Rev Cancer. 2013 Jan;13(1):51-65
pubmed: 23235911
Mutagenesis. 1998 May;13(3):287-305
pubmed: 9643589
Expert Rev Gastroenterol Hepatol. 2020 Jun;14(6):425-433
pubmed: 32441160
Virchows Arch. 2018 Nov;473(5):567-575
pubmed: 30066203
Nat Commun. 2021 Mar 5;12(1):1454
pubmed: 33674602
J Invest Dermatol. 1996 Jul;107(1):101-7
pubmed: 8752847
Nat Commun. 2017 Mar 28;8:14844
pubmed: 28348409
Bioinformatics. 2016 Sep 15;32(18):2877-9
pubmed: 27273669
Metabolites. 2020 Aug 25;10(9):
pubmed: 32854444
Clin Transl Med. 2022 May;12(5):e810
pubmed: 35560527
Int J Mol Sci. 2019 Feb 15;20(4):
pubmed: 30769921
Mol Pharmacol. 2007 Nov;72(5):1380-90
pubmed: 17724089
Mutagenesis. 2008 Sep;23(5):399-405
pubmed: 18515815
PLoS One. 2014 Aug 22;9(8):e105676
pubmed: 25148045
Biosci Rep. 2016 Jul 07;36(4):
pubmed: 27247425
Cancer Cell. 2020 Aug 10;38(2):167-197
pubmed: 32649885
Ann Appl Stat. 2013 Mar 1;7(1):523-542
pubmed: 23745156
J Invest Dermatol. 2003 May;120(5):707-14
pubmed: 12713571
Nucleic Acids Res. 2019 Jan 8;47(D1):D442-D450
pubmed: 30395289
Cancer Res. 2020 Jul 1;80(13):2764-2774
pubmed: 32345674
Front Immunol. 2017 Feb 02;8:71
pubmed: 28210259
Biochim Biophys Acta Rev Cancer. 2019 Aug;1872(1):37-48
pubmed: 31152823
Science. 2021 Aug 13;373(6556):760-767
pubmed: 34385390
Nat Biotechnol. 2020 Oct;38(10):1159-1163
pubmed: 32541957
Bioinformation. 2007 May 20;2(1):5-7
pubmed: 18084642
Mol Cell Proteomics. 2018 Jun;17(6):1239-1244
pubmed: 29487113
Biochim Biophys Acta. 2014 Nov;1843(11):2432-7
pubmed: 25003315
Cancer Res. 2010 Feb 1;70(3):1247-55
pubmed: 20086178
Mol Oncol. 2014 Feb;8(1):142-9
pubmed: 24210755
Nat Genet. 2015 Sep;47(9):1038-1046
pubmed: 26192915
Best Pract Res Clin Gastroenterol. 2010 Dec;24(6):873-82
pubmed: 21126700
Nucleic Acids Res. 2016 Jan 4;44(D1):D463-70
pubmed: 26467476
Expert Opin Drug Metab Toxicol. 2008 Jun;4(6):697-720
pubmed: 18611112
Gut. 2010 Dec;59(12):1606-16
pubmed: 20876775
J Proteome Res. 2020 Jul 2;19(7):2890-2897
pubmed: 32168452
Cancer Med. 2019 May;8(5):2360-2371
pubmed: 30868765
Redox Biol. 2021 Jun;42:101870
pubmed: 33509708
Prostaglandins Leukot Essent Fatty Acids. 2013 Jan;88(1):43-7
pubmed: 22515942
Nat Rev Cancer. 2021 Dec;21(12):753-766
pubmed: 34417571
Carcinogenesis. 2002 Dec;23(12):2095-102
pubmed: 12507933
Biomolecules. 2020 Feb 17;10(2):
pubmed: 32079324
Surgery. 1997 Nov;122(5):874-81
pubmed: 9369886
Sci Rep. 2017 Aug 30;7(1):9956
pubmed: 28855537
Mol Omics. 2020 Feb 17;16(1):6-18
pubmed: 31755509
BMC Bioinformatics. 2017 Jul 10;18(1):331
pubmed: 28693421
Oncotarget. 2018 Apr 17;9(29):20508-20523
pubmed: 29755668
Pathol Oncol Res. 2018 Apr;24(2):367-372
pubmed: 28540486
Redox Biol. 2021 Jul;43:101970
pubmed: 33887608